CONTEXT: RET/PTC rearrangements have been reported in papillary thyroid carcinomas with variable frequency in studies that used different detection methods. OBJECTIVE: Our objective was to determine the role of different detection methods and tumor genetic heterogeneity on RET/PTC detection. DESIGN: Sixty-five papillary carcinomas were analyzed for RET/PTC1 and RET/PTC3 using five detection methods: standard-sensitivity RT-PCR, high-sensitivity RT-PCR, real-time LightCycler RT-PCR, Southern blot analysis, and fluorescence in situ hybridization. RESULTS: RET/PTC rearrangements were detected by standard-sensitivity RT-PCR in 14 tumors. High-sensitivity RT-PCR detected RET/PTC in all of these and in 12 additional cases, where th...
Objective: Chromosomal rearrangements of the RET proto-oncogene is one of the most common molecular ...
Background:Evidence for an increased prevalence of BRAF(V600E) mutations has been documented in rece...
Thyroid carcinoma is the most frequent endocrine cancer accounting for 5-10% of thyroid nodules. Pap...
CONTEXT: RET/PTC rearrangements have been reported in papillary thyroid carcinomas with variable ...
OBJECTIVE: The activation of RET proto-oncogene, through different types of chromosomal translocatio...
Objective: The activation of RET proto-oncogene, through different types of chromosomal transloca-ti...
OBJECTIVE: RET proto-oncogene rearrangements (ret/PTCs) represent the most common genetic alteration...
Context : The prevalence of Rearranged during Transfection/Papillary Thyroid Carcinoma (RET/PTC) rea...
Background: Activation of the RET proto-oncogene, located on the long arms of chromosome 10, contrib...
Fine-needle aspiration cytology (FNAC) is the primary means to distinguish benign thyroid...
Background: Evidence for an increased prevalence of BRAF(V600E) mutations has been documented in rec...
PubMed ID: 18393128Objective: In recent years, thyroid cancer has been at the forefront of molecular...
none6RET/PTC1 and RET/PTC3 are the markers for papillary thyroid carcinoma. Their reported prevalenc...
The aim of this study is to investigate additional genetic alterations in papillary thyroid carcinom...
CONTEXT: The homogeneous distribution of BRAF V600E in papillary thyroid carcinoma (PTC) has been ca...
Objective: Chromosomal rearrangements of the RET proto-oncogene is one of the most common molecular ...
Background:Evidence for an increased prevalence of BRAF(V600E) mutations has been documented in rece...
Thyroid carcinoma is the most frequent endocrine cancer accounting for 5-10% of thyroid nodules. Pap...
CONTEXT: RET/PTC rearrangements have been reported in papillary thyroid carcinomas with variable ...
OBJECTIVE: The activation of RET proto-oncogene, through different types of chromosomal translocatio...
Objective: The activation of RET proto-oncogene, through different types of chromosomal transloca-ti...
OBJECTIVE: RET proto-oncogene rearrangements (ret/PTCs) represent the most common genetic alteration...
Context : The prevalence of Rearranged during Transfection/Papillary Thyroid Carcinoma (RET/PTC) rea...
Background: Activation of the RET proto-oncogene, located on the long arms of chromosome 10, contrib...
Fine-needle aspiration cytology (FNAC) is the primary means to distinguish benign thyroid...
Background: Evidence for an increased prevalence of BRAF(V600E) mutations has been documented in rec...
PubMed ID: 18393128Objective: In recent years, thyroid cancer has been at the forefront of molecular...
none6RET/PTC1 and RET/PTC3 are the markers for papillary thyroid carcinoma. Their reported prevalenc...
The aim of this study is to investigate additional genetic alterations in papillary thyroid carcinom...
CONTEXT: The homogeneous distribution of BRAF V600E in papillary thyroid carcinoma (PTC) has been ca...
Objective: Chromosomal rearrangements of the RET proto-oncogene is one of the most common molecular ...
Background:Evidence for an increased prevalence of BRAF(V600E) mutations has been documented in rece...
Thyroid carcinoma is the most frequent endocrine cancer accounting for 5-10% of thyroid nodules. Pap...